IPAH is defined as a sporadic condition of unknown etiology, distinguished from other PAH subtypes by the absence of both an identifiable underlying cause and a family history of PAH. The packet's known_genes field contains no entries, consistent with the non-heritable, sporadic character of this disease entity. No inheritance pattern is recorded in the packet. The clinical definition explicitly states that the etiology of IPAH is unknown.

No diagnostic methods or testing criteria are specified in the current packet for IPAH. The hallmark measurable hemodynamic parameters characterizing the condition—elevated pulmonary artery pressure, increased pulmonary vascular resistance, and pulmonary arterial hypertension—are documented in the phenotype data as very frequently present (80–99%). Dyspnea is present in all individuals (100%). Right ventricular hypertrophy and abnormal jugular venous morphology occur in 80–99% of documented cases. The packet contains no newborn screening designation for IPAH.

Two FDA-approved drugs with active market status appear in the packet's approved_treatments field for IPAH: epoprostenol (Veletri, NDA approval June 2008) and epoprostenol sodium (Flolan, NDA approval September 1995). The packet's orphan drug records additionally list the following drugs with FDA-approved status for pulmonary arterial hypertension: bosentan (Tracleer), selexipag (Uptravi), tadalafil (Adcirca), ambrisentan (Letairis), iloprost inhalation solution (Ventavis), macitentan (Opsumit), and treprostinil inhalation solution (Tyvaso). One orphan designation entry in the packet—zamicastat—carries a WITHDRAWN status and does not represent a current treatment option. Several additional compounds hold DESIGNATED (not approved) orphan drug status for PAH, indicating an active investigational pipeline. No entries appear in the packet's foundational_therapies field.

The packet's clinical definition characterizes IPAH as progressive and potentially fatal. No additional natural history data, survival estimates, or disease trajectory details are present in the packet's natural_history field. The progressive elevation of pulmonary arterial resistance with attendant right heart failure represents the core disease course described in the packet definition.

The packet records 103 active clinical trials associated with IPAH in ClinicalTrials.gov. Trials with detailed records in the current packet include: NCT07365332, an adaptive Phase 3 program evaluating IKT-001 in pulmonary arterial hypertension (recruiting, Inhibikase Therapeutics, through December 2029); NCT07073820, a Phase 2 extension study of PF-07868489 in pulmonary arterial hypertension (recruiting, Pfizer, through July 2028); NCT05649748, a Phase 2 extension study of treprostinil palmitil inhalation powder (TPIP) for PAH (active-not-recruiting, Insmed, through December 2026); NCT03492177, a Phase 2 study of selexipag dosing in pediatric PAH (active-not-recruiting, Actelion, through December 2026); NCT06053580, a Phase 2 evaluation of valsartan for pulmonary hypertension (recruiting, University of Washington, through July 2027); and NCT07613099, a Phase 3 fibrotic disease activity imaging study in cardiopulmonary disorders using 18F-FAPI-74 PET/CT (recruiting, National Heart, Lung, and Blood Institute, through May 2033).